Patents Assigned to Sandoz Pharmaceuticals Corp.
-
Patent number: 5399360Abstract: A ketotifen pharmaceutical composition adapted for once-a-day oral administration e.g. based on a fat matrix.Type: GrantFiled: August 11, 1993Date of Patent: March 21, 1995Assignee: Sandoz Pharmaceuticals Corp.Inventors: Hansruedi Surer, Aldo Riva
-
Patent number: 5321016Abstract: The invention discloses certain substituted .alpha.-aminoacids having the formula ##STR1## where m and n are 1 or 2, and R, R.sub.1, R.sub.2, R.sub.3 and Y have various significances, which compounds are useful in treating epilepsy, disorders associated with excess GH or LH secretion, anxiety, schizophrenia, depression, CNS degenerative disorders, cerebral hypoxic conditions and stress-related psychiatric disorders.Type: GrantFiled: September 18, 1992Date of Patent: June 14, 1994Assignee: Sandoz Pharmaceuticals Corp.Inventors: Paul L. Herrling, Werner Muller
-
Patent number: 5162311Abstract: The invention discloses certain substituted .alpha.-aminoacids having the formula ##STR1## where m and n are 1 or 2, and R, R.sub.1, R.sub.2, R.sub.3 and Y have various significances, which compounds are useful in treating epilepsy, disorders associated with excess GH or LH secretion, anxiety, schizophrenia, depression, CNS degenerative disorders, cerebral hypoxic conditions and stress-related psychiatric disorders.Type: GrantFiled: August 19, 1991Date of Patent: November 10, 1992Assignee: Sandoz Pharmaceuticals Corp.Inventors: Paul L. Herrling, Werner Muller
-
Patent number: 5141932Abstract: The invention discloses certain 5-aryl-substituted-2,3-dihydro-imidazo[1,2-a]furo- and thieno pyridines useful as PAF receptor antagonists and for treating tumors, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-mediated bronchoconstriction and extravasation, for controlling hyperreactive airways, for protecting against endotoxin-induced hypotension and death and for treating tumors.Type: GrantFiled: December 4, 1990Date of Patent: August 25, 1992Assignee: Sandoz Pharmaceuticals Corp.Inventors: William J. Houlihan, Seung H. Cheon
-
Patent number: 5010067Abstract: An injectable pharmaceutical mixture comprises:(A) a water-oil emulsion vehicle comprising:(a) about 5 to 25% fatty acid triglycerides;(b) sufficient physiologically acceptable emulsifying agent, e.g. from about 0 to 1.2% egg phosphatides, purified; andthe balance water, with sufficient alkali metal hydroxide added to adjust to an alkaline pH: and(B) an active ingredient which is a PAF receptor inhibitor or anti-tumor agent, which is an ether or carbamoyl phospholipid salt.Type: GrantFiled: July 19, 1988Date of Patent: April 23, 1991Assignee: Sandoz Pharmaceuticals Corp.Inventors: Dean A. Handley, William J. Houlihan, David B. Weinstein
-
Patent number: 4925851Abstract: The invention discloses certain 2- or 4-substituted-[2-(1H-imidazol-1-yl)ethyl]piperidines useful as anti-tumor agents, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions in treating tumors.Type: GrantFiled: May 23, 1989Date of Patent: May 15, 1990Assignee: Sandoz Pharmaceuticals Corp.Inventor: William J. Houlihan
-
Patent number: 4914096Abstract: The invention discloses certain 6-aryl-substituted-4H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,4]diazepines useful as PAF inhibitors, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-induced blood platelet aggregation, PAF-mediated bronchoconstriction and extravasation, PAF-induced hypotension, PAF-induced ischemic bowel disease and PAF-mediated, endotoxin induced lung injury, for controlling hyperreactive airways and for protecting against endotoxin-induced hypotension and death.Type: GrantFiled: March 31, 1989Date of Patent: April 3, 1990Assignee: Sandoz Pharmaceuticals Corp.Inventors: William J. Houlihan, Seung H. Cheon
-
Patent number: 4910206Abstract: The invention discloses certain 5-hetero or aryl-substituted-imidazo[2,1-a]isoquinolines useful as platelet activating factor (PAF) receptor antagonists, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-mediated bronchoconstriction and extravassation and PAF-mediated, endotoxin-induced lung injury, and for controlling hyperreactive airways induced by PAF or allergin. In addition, the invention discloses the use of a select group of said compounds as anti-tumor agents.Type: GrantFiled: January 27, 1989Date of Patent: March 20, 1990Assignee: Sandoz Pharmaceuticals Corp.Inventor: William J. Houlihan
-
Patent number: 4898928Abstract: Water-soluble polyacetal or polyketal having the formula ##STR1## wherein R.sub.1, and R.sub.2 are aliphatic, cycloaliphatic or aromatic groups, for ketals; R.sub.1 is hydrogen and R.sub.2 is aliphatic, cycloaliphatic, or aromatic groups for acetals; R.sub.3 and R.sub.4 are also aliphatic, alkoxy, cycloaliphatic or aromatic groups X represents groups as (CH.sub.2).sub.n, O(CH.sub.2).sub.N O or ##STR2## that connect the pendant unsaturation to the aliphatic, cycloaliphatic or aromatic R.sup.4 groups, the ratio of a to b is 0.5 to 10, and n is 10-100.Type: GrantFiled: March 7, 1988Date of Patent: February 6, 1990Assignee: Sandoz Pharmaceuticals Corp.Inventors: Jorge Heller, Donald W. H. Penhale, Steve Y. Ng
-
Patent number: 4739073Abstract: Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl(CH.sub.2).sub.m --, whereinR.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, andm is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.Type: GrantFiled: March 4, 1985Date of Patent: April 19, 1988Assignee: Sandoz Pharmaceuticals Corp.Inventor: Faizulla G. Kathawala
-
Patent number: 4713441Abstract: Water soluble polyacetals having molecular weights from about 5,000-30,000 are formed by condensing three monomers, e.g. a divinyl ether, a water soluble glycol and a diol. The invention is used for the bioerodible controlled release of therapeutic agents from the polyacetal hydrogel.Type: GrantFiled: August 1, 1986Date of Patent: December 15, 1987Assignee: Sandoz Pharmaceuticals Corp.Inventors: Jorge Heller, Donald W. H. Penhale
-
Patent number: 4686237Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is C.sub.1-3 alkyl, andZ is ##STR2## wherein R.sub.7 is hydrogen, R.sub.8 or M, whereinR.sub.8 is a physiologically acceptable and hydrolyzable ester group, andM is a pharmaceutically acceptable cation,the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.Type: GrantFiled: February 19, 1986Date of Patent: August 11, 1987Assignee: Sandoz Pharmaceuticals Corp.Inventor: Paul L. Anderson
-
Patent number: 4681898Abstract: Compounds of the formula ##STR1## where n is 0 or 1,R is alkyl, phenyl or R.sub.4 -substituted phenyl,R.sub.2 and R.sub.3 are, independently, alkyl orR.sub.2 and R.sub.3 together with N is ##STR2## m is 1, 2 or 3, R.sub.1 and R.sub.4 are, independently hydrogen, halo, alkyl or alkoxy, andR.sub.5 is hydrogen or alkyl of 1 to 6 carbon atomsor their pharmaceutically acceptable salts are useful as anti-diabetic agents, in particular, as hypoglycemic agents or inhibitors of post-prandial hypoglycemia.Type: GrantFiled: May 8, 1984Date of Patent: July 21, 1987Assignee: Sandoz Pharmaceuticals Corp.Inventor: Jeffrey Nadelson
-
Patent number: 4677211Abstract: 7-Substituted lower alkyl hept-6-enoates and 4-hydroxytetrahydropyran-2-ones bearing 6-olefinic substituents (e.g.,) ethyl erythro-3,5-dihydroxy-7-phenyl-hept-6-enoates are prepared by a multi-step process. The process involves 3-protected-lower alkyl 3,5-dihydroxy-hept-6-enoates, which are obtained by cleaving corresponding 6.alpha.-vinyl-4.beta.-protected hydroxy-tetrahydro 2H-pyran-2-ones. The final products are useful as anti hypercholesteremic agents.Type: GrantFiled: July 26, 1985Date of Patent: June 30, 1987Assignee: Sandoz Pharmaceuticals Corp.Inventors: Charles F. Jewell, Jr., James R. Wareing
-
Patent number: 4673672Abstract: The invention discloses substituted 2-[hydroxy(tetrahydro)-5-oxo-(2- and 3-furanyl or 2-thienyl) alkoxyphosphinyloxy]-alkanaminium hydroxide inner salt-4-oxides useful as anti-tumor agents, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for treating tumors.Type: GrantFiled: June 17, 1986Date of Patent: June 16, 1987Assignee: Sandoz Pharmaceuticals Corp.Inventors: William J. Houlihan, Mark L. Lee
-
Patent number: 4673674Abstract: Diazepinoindoles or pharmaceutically acceptable acid addition salts thereof are useful as antidepressant, conflict reducing or neuroleptic agents.Type: GrantFiled: February 21, 1985Date of Patent: June 16, 1987Assignee: Sandoz Pharmaceuticals Corp.Inventor: Fulvio Gadient
-
Patent number: 4613610Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is C.sub.1-6 alkyl not containing an asymmetric carbon atom,each of R.sub.2 and R.sub.5 is independently hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenyl, phenoxy or benzyloxy,each of R.sub.3 and R.sub.6 is independently hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,each of R.sub.4 and R.sub.7 is independently hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, with the provisos that not more than one of R.sub.2 and R.sub.3 is trifluoromethyl, not more than one of R.sub.2 and R.sub.3 is phenoxy, not more than one of R.sub.2 and R.sub.3 is benzyloxy, not more than one of R.sub.5 and R.sub.6 is trifluoromethyl, not more than one of R.sub.5 and R.sub.6 is phenoxy, and not more than one of R.sub.5 and R.sub.6 is benzyloxy,X is --(CH.sub.2).sub.m --, --CH.dbd.CH--, --CH.dbd.CH--CH.sub.2 -- or --CH.sub.2 --CH.dbd.Type: GrantFiled: June 6, 1985Date of Patent: September 23, 1986Assignee: Sandoz Pharmaceuticals Corp.Inventor: James R. Wareing